All sponsors

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. $6990.HK

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS35
PHASE 3 / 2-310
RECRUITING20
READOUTS ≤12 MONTHS14
READOUT SLIPPED >6 MO47%

Delay Index: of 15 active trials registered more than a year ago, 7 have moved their primary completion (readout) date by more than 6 months since first registration (median +1.2 months). See all sponsors →

Open Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. on the live radar map → 📅 $6990.HK readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
SKB264
NCT05347134
P3Active, not recruitingTriple Negative Breast Cancer2542023-11-30
SKB264
NCT05870319
P3Active, not recruitingNon-small Cell Lung Cancer3762024-07-11 (-10 mo)
SKB264
NCT05351788
P2RecruitingNon-small Cell Lung Cancer1102026-08 (+36 mo)
SKB264
NCT06448312
P3Active, not recruitingNon-Small Cell Lung Cancer4062026-11
A166
NCT06968585
P3Active, not recruitingHER2-positive Breast Cancer3652026-11-30 (+12 mo)
SKB264
NCT06711900
P3Active, not recruitingNon-Small Cell Lung Cancer4322026-12
SKB264
NCT05631262
P2Active, not recruitingSelected Subjects With Advanced Solid Tumors3212026-12-30 (+26 mo)
KL590586 Capsule
NCT05265091
P1/2Active, not recruitingAdvanced Solid Tumor4142026-12-31 (+19 mo)
SKB264
NCT06081959
P3RecruitingMetastatic Breast Cancer3762026-12-31 (+9 mo)
SKB518
NCT07019675
P2RecruitingLung Carcinoma1922027-02-20 (-4 mo)
SKB264
NCT06279364
P3Active, not recruitingTriple Negative Breast Cancer5372027-04 (+9 mo)
SKB264
NCT06670196
P3Active, not recruitingNon-Small Cell Lung Cancer4202027-05
SKB571 for injection
NCT07308106
P2RecruitingNon-small Lung Cancer702027-06-30
SKB264
NCT07071337
P3RecruitingMetastatic Breast Cancer4302027-07
Sacituzumab Tirumotecan
NCT07329322
P2RecruitingNon-Small Cell Lung Cancer302027-08-31
SKB571 for injection
NCT07564466
P2RecruitingGastrointestinal Tumors1602027-08-31
A166
NCT07299825
P2RecruitingHer 2 Positive Breast Cancer402027-09-20
KL-A167
NCT05294172
P3Active, not recruitingNasopharyngeal Carcinoma; Recurrent or Metastatic2952027-12 (+42 mo)
SKB264+SKB118
NCT07854509
P2Not yet recruitingNon-Squamous Non-Small Cell Lung Cancer1102027-12-30
SKB518 for injection
NCT07448922
P2RecruitingAdvanced Gynecological Malignancies2802027-12-31
SKB264
NCT07341100
P2Active, not recruitingOvarian Epithelial Cancer202028-01
SKB571 for injection
NCT07230405
P2RecruitingLung Cancer (Non-Small Cell)2952028-01-19 (+1 mo)
SKB571
NCT07814066
P2Not yet recruitingPancreatic Cancer302028-02-28
Sacituzumab tirumotecan
NCT07324629
P2RecruitingThymic Carcinoma302028-04
SKB315
NCT07609667
P2Not yet recruitingGastroesophageal Junction Adenocarcinoma802028-06-30
SKB264+SKB118
NCT07697586
P2RecruitingNSCLC2062028-08
SKB571
NCT07668154
P2RecruitingHNSCC1202028-09-30
SKB571 for injection
NCT07622186
P2RecruitingNon-Small Cell Lung Cancer1502028-12-31
SKB500
NCT07700667
P2RecruitingEsophageal Squamous Cell Carcinoma1202028-12-31
SKB500 Powder for Injection
NCT07296809
P2RecruitingSmall Cell Lung Cancer802028-12-31
SKB565
NCT07545265
P1/2RecruitingAdvanced Solid Tumors1802029-03
SKB118 Injection
NCT07586943
P1/2RecruitingAdvanced Solid Tumors5302029-12
SKB105 for injection Monotherapy
NCT07380386
P1/2RecruitingAdvanced Solid Tumors2562029-12-31
SKB103 for injection monotherapy
NCT07459998
P1/2RecruitingAdvanced Solid Tumors2772029-12-31
SKB103 monotherapy
NCT07774624
P1/2Not yet recruitingBreast Cancer1402029-12-31